Cognition Therapeutics is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD 2024 Alzheimer’s & Parkinson’s Diseases Conference. Two posters summarize proteomic analyses from the Phase 2 SEQUEL study which measured the impact of CT1812 on synapse function as determined by changes in brain wave patterns recorded by quantitative electroencephalogram. These posters identify candidate protein biomarkers that correlate with improvements observed in SEQUEL participants treated with CT1812, Cognition’s lead candidate. Among the proteins identified, those that were strongly correlated with CT1812 treatment effects were associated with protein trafficking, autophagy, neuroinflammation and microglial response. The third poster summarizes proteomic analyses from the Phase 1 SPARC study, which was designed to measure the impact of CT1812 on synaptic density. Pathways identified in these proteomic analyses support a role for CT1812 in modulating Abeta biology and neuroinflammation, among other disease-relevant processes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CGTX:
- Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
- Cognition Therapeutics to Present at the TD Cowen Health Care Conference
- Cognition Therapeutics Rewards Executives with Stock for Milestones
- New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
- Cognition Therapeutics identifies key proteins involved in Alzheimer’s disease